Squarepoint’s Repare Therapeutics RPTX Stock Holding History

Squarepoint’s Portfolio RPTX Stock Details RPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-14,485	Closed	-$37.7K	–	4865
2025 Q4	$37.7K	Sell	14,485 -50,758	-78%	-$102K	﹤0.01%	4142
2025 Q3	$115K	Buy	+65,243	New	+$104K	﹤0.01%	4085
2025 Q2	–	Sell	-11,890	Closed	-$11.7K	–	4977
2025 Q1	$11.7K	Buy	+11,890	New	+$14.3K	﹤0.01%	4458
2024 Q4	–	Sell	-74,993	Closed	-$258K	–	5425
2024 Q3	$258K	Sell	74,993 -67,981	-48%	-$224K	﹤0.01%	3548
2024 Q2	$472K	Buy	142,974 +115,916	+428%	+$413K	﹤0.01%	3122
2024 Q1	$127K	Sell	27,058 -27,429	-50%	-$176K	﹤0.01%	3743
2023 Q4	$398K	Buy	54,487 +36,307	+200%	+$203K	﹤0.01%	3176
2023 Q3	$220K	Buy	+18,180	New	+$188K	﹤0.01%	3358

Squarepoint's RPTX Position: Q1 2026 in Review

Squarepoint sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 14,485 shares — an estimated $37.7K sold.

Squarepoint first reported a position in RPTX in Q3 2023 and held it in 8 quarters. The position peaked at $472K in Q2 2024. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.

Squarepoint reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 14,485 Repare Therapeutics shares in Q1 2026, an estimated $37.7K.
Squarepoint first reported a position in Repare Therapeutics in Q3 2023 and held it in 8 quarters.
Squarepoint's Repare Therapeutics position peaked at $472K in Q2 2024.
0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.